UK markets close in 3 hours 10 minutes

Orphazyme A/S (ORPHA.CO)

Copenhagen - Copenhagen Real-time price. Currency in DKK
Add to watchlist
1.6100-0.0020 (-0.12%)
As of 01:30PM CEST. Market open.
Full screen
Previous close1.6120
Bid1.6100 x 0
Ask1.6950 x 0
Day's range1.6100 - 1.6900
52-week range1.1000 - 40.7200
Avg. volume107,742
Market cap56.853M
Beta (5Y monthly)1.01
PE ratio (TTM)N/A
EPS (TTM)-17.9400
Earnings date20 Sept 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est108.00
  • Globe Newswire

    Resolutions passed at the Annual General Meeting

    Orphazyme A/SCompany announcementNo. 33/2022 www.orphazyme.comCompany Registration No. 32266355 Copenhagen, Denmark, June 29, 2022 – Orphazyme A/S (ORPHA.CO) (the “Company”), today held its Annual General Meeting, at which the Annual General Meeting: Financial year 2021 and 2022 Took note of the Board of Directors’ report on the Company’s activities in the past financial year;Adopted the Company’s Annual Report 2021;Adopted that the loss related to the financial year 2021 is carried forward;Appr

  • Globe Newswire

    Updated notice to holders of ADSs regarding termination of Deposit Agreement

    Orphazyme A/SCompany announcement No. 32/2022www.orphazyme.comCompany Registration No. 32266355 NOTICE TO HOLDERS OF AMERICAN DEPOSITARY SHARES (“ADSs”) EVIDENCED BYAMERICAN DEPOSITARY RECEIPTS (“ADRs”) REPRESENTING DEPOSITED COMMON SHARES OF:ORPHAZYME A/S ONE ADS REPRESENTS ONE COMMON SHARECUSIP: 687305102 AND UNDERLYING ISIN: DK0060910917 Copenhagen, Denmark, June 20, 2022 – Orphazyme A/S (ORPHA.CO) (“Orphazyme” or the “Company”), hereby provides notice to holders of American Depositary Shares

  • Globe Newswire

    Correction: Orphazyme Announces Publication of 2021 Financial Results and Annual Report

    Orphazyme A/SCompany announcementNo. 30/2022 Annual Company Registration No. 32266355 [Correction: Hereby including the ESEF versions] Copenhagen, Denmark, June 7, 2022 – Orphazyme A/S (ORPHA.CO) (“Orphazyme” or the “Company”), today reports its financial results for the period from January 1, 2021, to December 31, 2021, and publishes its Annual Report. In 2021, and until recently, the primary focus of Orphazyme was on seeking marketing authorization in the United States